<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692717</url>
  </required_header>
  <id_info>
    <org_study_id>ALHHYP0512OR-I</org_study_id>
    <secondary_id>Versão 01 28.05.2012</secondary_id>
    <nct_id>NCT01692717</nct_id>
  </id_info>
  <brief_title>Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <brief_summary>
    <textblock>
      The objective of this clinical study, randomized, crossover is to evaluate the
      pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide)
      Laboratory Hypermarcas S / A, in relation to drugs Citalor ® (atovastatina - Pfizer) and
      Hyzaar ® (losartan + hydrochlorothiazide - Merck Sharp &amp; Dohme) by comparing the serum
      concentration of analytes unchanged (AT, LS and HCTZ) in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetic profile of the drug will also be assessed by comparing the serum
      concentration of active metabolites following:

        -  O-hydroxy atorvastatin (2-Hydroxy atorvastatin, O-HAT): metabolite of AT

        -  carboxylic acid (E-3174, LS-CA): active metabolite of LS
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary pharmacokinetic parameters for the exercise of comparability will be unchanged dosages of analytes (AT, LS and HCTZ), assessed by AUC, Tmax, Cmax and T1 / 2.</measure>
    <time_frame>0h00, 0h15, 0h30, 0h45, 1h00, 1h15, 1h30, 1h45, 2h00, 2h30, 3h00, 3h30, 4h00, 4h30, 5h00, 6h00, 8h00, 10h00, 12h00, 18h00, 24h00, 36h00, 48h00, 56h00 e 72h00.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters are side dosages of active metabolites O-HAT and E-3174, measured by AUC, Tmax, Cmax and T1 / 2.</measure>
    <time_frame>0h00, 0h15, 0h30, 0h45, 1h00, 1h15, 1h30, 1h45, 2h00, 2h30, 3h00, 3h30, 4h00, 4h30, 5h00, 6h00, 8h00, 10h00, 12h00, 18h00, 24h00, 36h00, 48h00, 56h00 e 72h00.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Citalor (Atorvastatin) - Pfizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide + Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp &amp; Dohme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin + Hydrochlorothiazide + Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>10 mg</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Hydrochlorothiazide + Losartan</arm_group_label>
    <arm_group_label>Atorvastatin + Hydrochlorothiazide + Losartan</arm_group_label>
    <other_name>Citalor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide + Losartan</intervention_name>
    <description>12.5 mg + 50 mg</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Hydrochlorothiazide + Losartan</arm_group_label>
    <arm_group_label>Atorvastatin + Hydrochlorothiazide + Losartan</arm_group_label>
    <other_name>Hyzaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide + Losartan + Atorvastatin</intervention_name>
    <description>12.5 mg + 50 mg + 10 mg</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Hydrochlorothiazide + Losartan</arm_group_label>
    <arm_group_label>Atorvastatin + Hydrochlorothiazide + Losartan</arm_group_label>
    <other_name>Polipílula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirm voluntary participation and agree to all the purposes of the study by signing
             and dating the IC in two ways;

          2. Age between 18 and 55 years, regardless of sex, clinically healthy and present
             laboratory parameters within normal limits;

          3. BMI ≥ 18.5 and ≤ 30.

        Exclusion Criteria:

          1. Participation in clinical trials in the 12 months preceding the survey;

          2. History of hypersensitivity reactions to atorvastatin, losartan hydrochlorothiazide
             and / or any other ingredients of medicines;

          3. Alterations in clinical and laboratory criteria that interfere Principal Investigator
             on the study results;

          4. Presence of pulmonary diseases, cardiovascular, neurological, endocrine,
             gastrointestinal, genitourinary or other systems;

          5. Acute illness during the 07 days preceding the start of the study;

          6. Chronic disease that determine drug delivery, such as hypertension, diabetes or any
             other that requires continuous use of any medicine, including use of vitamins, mineral
             supplements and OTCs (over-the-counter);

          7. Having made regular use of medication in the last 02 weeks before the onset of the
             study. The use of any medication that does not interfere with the physician's judgment
             on the pharmacokinetics of the drug under study, will not be considered as an
             exclusion criterion.

          8. Use of medications that interact with any medications association;

          9. History of or current use for at least 12 months of tobacco;

         10. Current or previous history (under 12 months) of illicit drug use;

         11. At the discretion of the Principal Investigator of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Frederico, physician</last_name>
    <phone>55 19 38716399</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>LAL Clínica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Frederico, physician</last_name>
      <phone>55 19 38716399</phone>
      <email>alexandre@lalclinica.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

